35179
document
Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer : a randomised controlled study . Adjuvant immunochemotherapy using the antitumour polysaccharide sizofiran ( SPG ) , an extract from the culture broth of Schizophyllum commune Fries , was prescribed randomly for 386 Japanese patients with resectable gastric cancer . Although the overall survival probability for 5 years did not differ between the SPG and control groups , in 264 patients with curatively resected cancer , the probability to 5 year survival and to recurrence in the sizofiran-administered patients was better than in the controls . In the multivariate analysis , four of six prognostic factors correlated with the prognosis of the 264 patients who underwent curative surgery , that is , nodal involvement ( chi 2 = 21.426 , P = less than 0.0001 ) , age distribution ( chi 2 = 9.262 , P = 0.010 ) , sizofiran administration ( chi 2 = 6.507 , P = 0.011 ) , and primary tumour size ( chi 2 = 9.345 , P = 0.025 ) . Thus , patients with a curatively resected gastric cancer had a better prognosis when sizofiran was prescribed in combination with antitumour drugs .
35180
Intervention_Pharmacological
sizofiran
35181
Intervention_Pharmacological
Adjuvant immunochemotherapy using the antitumour polysaccharide sizofiran ( SPG )
35182
Intervention_Pharmacological
sizofiran
35183
Outcome_Mortality
overall survival probability
35184
Outcome_Physical
recurrence
35185
Outcome_Physical
nodal involvement
35186
Outcome_Other
age distribution
35187
Outcome_Other
sizofiran administration
35188
Outcome_Physical
primary tumour size
35189
Participant_Condition
386 Japanese patients with resectable gastric cancer .